BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $750 Million Repurchase to Date in FY25
Rhea-AI Summary
BD (NYSE: BDX) has announced several key financial decisions. The Board declared a quarterly dividend of $1.04 per common share, payable on March 31, 2025, to shareholders of record on March 10, 2025, indicating an annual dividend rate of $4.16 per share.
The company has already completed $750 million in stock repurchases in fiscal 2025. Additionally, the Board authorized the repurchase of up to 10 million additional shares of BD common stock, supplementing the remaining shares available under the 2021 authorization. The company maintains flexibility in executing these repurchases through various methods, with timing and volume determined by management based on market conditions and business factors.
Positive
- Completed $750 million in share repurchases in FY25
- New authorization for additional 10 million share repurchases
- Maintaining quarterly dividend of $1.04 per share ($4.16 annually)
- Strong capital return program indicating financial stability
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, BDX declined 0.88%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
The company also announced it repurchased
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts: | |
Media: | Investors: |
Troy Kirkpatrick | Adam Reiffe |
VP, Public Relations | Sr. Director, Investor Relations |
858.617.2361 | 201.847.6927 |
View original content:https://www.prnewswire.com/news-releases/bd-board-declares-dividend-authorizes-10-million-additional-share-repurchases-bd-completed-750-million-repurchase-to-date-in-fy25-302362403.html
SOURCE BD (Becton, Dickinson and Company)